Recent News

DREAMM-4 Trial Update of Belantamab Mafodotin in Myeloma

KEYNOTE-629: Pembrolizumab in Metastatic Cutaneous Squamous Cell Carcinoma

Novel First-in-Class Agent Shows Activity in High-Grade Serous Ovarian Cancer

Front-Line Immunotherapy for Locally Advanced Basal Cell Carcinoma: Case Studies

FDA Accepts Two Applications for Pembrolizumab in Triple-Negative Breast Cancer

Combined REMARRY and PURSUIT Trials to Assess Metastatic Colorectal Cancer

Vaccinating Against Pneumonia in Patients With Myeloma

Survival Update With Bevacizumab Plus Erlotinib in Certain Patients With NSCLC

Second-Line Treatment Alternatives for Metastatic Colorectal Cancer

Subgroup Analysis of Isatuximab-Based Therapy for Resistant Myeloma

ESMO World GI: Pembrolizumab Plus Ibrutinib Under Study in Metastatic Colorectal Cancer

Adding Platinum Doublet to Immunotherapy Combination in Advanced Lung Cancer

The Gut Microbiome's Response to Immunotherapy for Lung Cancer

AACR II: Antibody-Drug Conjugate Targets CLDN6/9 in Epithelial Ovarian Cancer

EHA25 Virtual: Adding Elotuzumab to Treatment Regimen in Newly Diagnosed Myeloma

3-Year TRAIN-2 Update on Neoadjuvant Therapy for HER2-Positive Breast Cancer

EHA25 Virtual: Quality of Life With Duvelisib Versus Ofatumumab in CLL

Health-Related Quality of Life With Cemiplimab for Skin Cancer

Does Anaplastic Thyroid Carcinoma Respond to PD-1 Blockade?

EHA25 Virtual: Does Administration Sequence of Ibrutinib/Obinutuzumab in CLL Affect Toxicity?

AACR II: Early Results With Dual Inhibitors of IGF and CDK4/6 in Lung Cancer

AACR II: Adding Interferon-Gamma to Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer

Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma

Immune-Mediated Adverse Events With Concomitant Radiotherapy and Immunotherapy

Interim Results of Trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC

Combining IL-7 With Pembrolizumab in Metastatic Triple-Negative Breast Cancer

EHA25 Virtual: Adding Isatuximab to Front-Line Standard of Care in High-Risk Myeloma

AACR II: Flat Dosing of Nivolumab in Patients Previously Treated for NSCLC

Subcutaneous Combination Therapy Approved by FDA for HER2-Positive Breast Cancer

HER2-Targeted Therapy With Trastuzumab Deruxtecan in Lung Cancer

Pembrolizumab Approved by FDA for Cutaneous Squamous Cell Carcinoma

ASCO20: 3-Year Update on Nivolumab Plus Ipilimumab as First-Line Treatment of NSCLC

ASCO20: Tucatinib Combination Therapy for Breast Cancer With Brain Metastases

EHA25 Virtual: Single-Agent Belantamab Mafodotin in Resistant Myeloma

ASCO20: Venetoclax Plus Obinutuzumab in Treatment-Naive CLL

ASCO20: Update on BCMA-Directed CAR-T Cell Therapy for Resistant Myeloma

ASCO20: Tiragolumab Plus Atezolizumab for PD-L1–Selected NSCLC

First-in-Class Immunotherapy With Azacitidine Under Study in AML

ASCO20: Can Radioiodine Plus Durvalumab Improve Outcomes in Resistant Thyroid Cancer?

ASCO20: KEYNOTE-355 Trial of Pembrolizumab Plus Chemotherapy in Triple-Negative Breast Cancer

ASCO20: Antibody-Drug Conjugate Active in CEACAM5-Expressing Nonsquamous NSCLC

ASCO20: Final Results From GENUINE Trial of Ublituximab Plus Ibrutinib in CLL

EHA25 Virtual: Adding Isatuximab to Carfilzomib and Dexamethasone in Resistant Myeloma

Biologic Therapies for Patient With Both Lung Cancer and Multiple Myeloma

ASCO20: Does Adding Trastuzumab to Radiotherapy Decrease Recurrence of Breast Cancer?

ASCO20: Update on Orvacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma

ASCO20: Longer-Term Follow-Up Supports Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma

ASCO20: Autologous Tumor Immunotherapy Plus Atezolizumab in Recurrent Ovarian Cancer

ASCO20: Trastuzumab Deruxtecan in HER2-Expressing Metastatic Colorectal Cancer

ASCO20: Cabozantinib Plus Atezolizumab for Castration-Resistant Prostate Cancer

EHA25 Virtual: Phase III Trial to Study Acalabrutinib-Based Combination in CLL

ASCO20: Antibody-Drug Conjugate Plus Bevacizumab in Platinum-Agnostic Ovarian Cancer

ASCO20: Treating Anaplastic Thyroid Cancer Based on Driver Mutations